Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cardiol Therapeutics Inc. - Class A Common Shares (NQ:CRDL)

1.345 -0.055 (-3.93%)

Streaming Delayed Price Updated: 11:05 AM EDT, Apr 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	150,208
Open	1.440
Bid (Size)	1.340 (1,800)
Ask (Size)	1.350 (3,600)
Prev. Close	1.400
Today's Range	1.334 - 1.440
52wk Range	0.7709 - 1.590
Shares Outstanding	65,352,279
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

On Tuesday, there are stocks with unusual volume. Let's take a look. ↗

March 31, 2026

Via Chartmill

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

December 01, 2025

(December 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company advancing anti-inflammatory and

Via PressReach

Performance

YTD	+35.3%	+35.3%
1 Month	+37.3%	+37.3%
3 Month	+34.5%	+34.5%
6 Month	+26.9%	+26.9%
1 Year	+58.2%	+58.2%

More News

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

December 01, 2025

Via Newsfile

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

August 06, 2025

Via PressReach

This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

June 02, 2025

Via Benzinga

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

April 16, 2025

Via Newsfile

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Terry Lynch to Board, Grants Options

March 27, 2025

Via Investor Brand Network

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart

February 20, 2025

Via Newsfile

Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today ↗

October 09, 2024

Via Benzinga

“Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances”

December 06, 2024

Via AB Newswire

3 Penny Stocks Ready to Break Out in 2025

November 29, 2024

Via MarketBeat

Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!

November 25, 2024

Via AB Newswire

“Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside”

November 21, 2024

Via AB Newswire

Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…

November 21, 2024

Via AB Newswire

CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study ↗

November 19, 2024

Via Benzinga

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

November 18, 2024

Via AB Newswire

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

November 18, 2024

Via Newsfile

“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”

November 13, 2024

Via AB Newswire

Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN

November 07, 2024

Via AB Newswire

“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”

November 05, 2024

Via AB Newswire

“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”

October 28, 2024

Via AB Newswire

Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX

October 23, 2024

Via AB Newswire

Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…

October 22, 2024

Via AB Newswire

AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday ↗

October 09, 2024

Via Benzinga

“Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…”

September 12, 2024

Via AB Newswire

Frequently Asked Questions

Is Cardiol Therapeutics Inc. - Class A Common Shares publicly traded?

Yes, Cardiol Therapeutics Inc. - Class A Common Shares is publicly traded.

What exchange does Cardiol Therapeutics Inc. - Class A Common Shares trade on?

Cardiol Therapeutics Inc. - Class A Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Cardiol Therapeutics Inc. - Class A Common Shares?

The ticker symbol for Cardiol Therapeutics Inc. - Class A Common Shares is CRDL on the Nasdaq Stock Market

What is the current price of Cardiol Therapeutics Inc. - Class A Common Shares?

The current price of Cardiol Therapeutics Inc. - Class A Common Shares is 1.345

When was Cardiol Therapeutics Inc. - Class A Common Shares last traded?

The last trade of Cardiol Therapeutics Inc. - Class A Common Shares was at 04/08/26 11:05 AM ET

What is the market capitalization of Cardiol Therapeutics Inc. - Class A Common Shares?

The market capitalization of Cardiol Therapeutics Inc. - Class A Common Shares is 87.90M

How many shares of Cardiol Therapeutics Inc. - Class A Common Shares are outstanding?

Cardiol Therapeutics Inc. - Class A Common Shares has 88M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.